Your browser is no longer supported. Please, upgrade your browser.
BMY Bristol-Myers Squibb Company daily Stock Chart
Bristol-Myers Squibb Company
IndexS&P 500 P/E29.87 EPS (ttm)2.20 Insider Own0.10% Shs Outstand2.33B Perf Week-0.68%
Market Cap152.77B Forward P/E8.92 EPS next Y7.36 Insider Trans-1.79% Shs Float2.33B Perf Month-2.67%
Income3.44B PEG2.13 EPS next Q1.50 Inst Own76.40% Short Float2.74% Perf Quarter16.20%
Sales26.15B P/S5.84 EPS this Y28.70% Inst Trans27.51% Short Ratio4.18 Perf Half Y37.39%
Book/sh10.81 P/B6.07 EPS next Y20.05% ROA13.60% Target Price73.40 Perf Year30.92%
Cash/sh13.98 P/C4.69 EPS next 5Y14.00% ROE39.40% 52W Range42.48 - 68.34 Perf YTD2.24%
Dividend1.80 P/FCF42.13 EPS past 5Y14.50% ROI25.40% 52W High-3.97% Beta0.76
Dividend %2.74% Quick Ratio3.70 Sales past 5Y6.60% Gross Margin69.90% 52W Low54.50% ATR1.18
Employees23300 Current Ratio3.80 Sales Q/Q5.60% Oper. Margin28.10% RSI (14)51.02 Volatility1.60% 1.84%
OptionableYes Debt/Eq1.41 EPS Q/Q-29.50% Profit Margin23.70% Rel Volume0.66 Prev Close65.17
ShortableYes LT Debt/Eq1.38 EarningsFeb 06 BMO Payout42.70% Avg Volume15.25M Price65.63
Recom1.90 SMA200.39% SMA501.42% SMA20022.99% Volume10,095,302 Change0.71%
Jan-06-20Resumed Citigroup Buy $73
Dec-13-19Upgrade Argus Hold → Buy $80
Nov-22-19Resumed Morgan Stanley Equal-Weight $60
Oct-17-19Resumed BofA/Merrill Buy $60
Aug-14-19Upgrade Atlantic Equities Neutral → Overweight $63
May-28-19Initiated Goldman Buy
May-20-19Downgrade Argus Buy → Hold
May-03-19Upgrade Barclays Equal Weight → Overweight $53 → $55
May-03-19Resumed JP Morgan Overweight $62
Jan-15-19Upgrade Societe Generale Sell → Buy
Oct-22-18Downgrade Citigroup Buy → Neutral
Oct-09-18Resumed Guggenheim Neutral
Aug-08-18Upgrade Atlantic Equities Underweight → Neutral
Apr-17-18Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-12-18Reiterated Citigroup Buy $78 → $70
Mar-20-18Reiterated JP Morgan Overweight $70 → $75
Feb-15-18Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-30-17Upgrade SunTrust Hold → Buy
Oct-16-17Downgrade Jefferies Buy → Hold
Sep-12-17Downgrade Hilliard Lyons Long-term Buy → Neutral
Feb-21-20 12:13PM  Ronald Muhlenkamp's Firm Buys 3 Stocks in 4th Quarter
06:59AM  Japan Ministry of Health, Labor and Welfare Approves Opdivo (nivolumab) for the Treatment of Patients with Unresectable Advanced or Recurrent Esophageal Cancer Business Wire
Feb-20-20 04:51PM  4 Most Popular Healthcare Stocks Among Hedge Funds: Q4 Rankings Insider Monkey
12:37PM  David Abrams Buys 2 Stocks in 4th Quarter
05:00AM  A Portfolio for Steady Dividends MoneyShow
Feb-19-20 10:29AM  Gilead poaches Bristol-Myers Squibb site head in continuing exec team remake American City Business Journals
09:51AM  Jim Simons: The Investing Guru Bets on These 3 Healthcare Stocks TipRanks
09:50AM  bluebird (BLUE) Q4 Earnings Miss Estimates, Revenues In Line Zacks
06:59AM  Bristol-Myers Squibb to Hold Investor Day on April 2 Business Wire
Feb-18-20 04:08PM  David Rolfe Adds 4 Stocks to Portfolio in 4th Quarter
08:00AM  Pfizer Stock Tumbled On Lackluster Earnings Should You Add Shares? Investor's Business Daily
Feb-15-20 02:30PM  Updated CheckMate -025 Results Show 26% of Patients Treated with Opdivo are Alive at Five Years in Patients with Previously Treated Advanced or Metastatic Renal Cell Carcinoma Business Wire
01:00PM  Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Continued Survival Benefit at 42-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma Business Wire
Feb-14-20 11:04AM  Agios' (AGIO) Q4 Loss Narrower Than Expected, Revenues Beat Zacks
09:55AM  Bristol-Myers Posts Bullish Growth But Is It Time To Add BMY Stock? Investor's Business Daily
09:52AM  Pharma Stock Roundup: ABBV, AGN Post Q4 Results, Another Alzheimer's Study Fails Zacks
09:07AM  Bristol-Myers' (BMY) CAR T Cell Therapy Gets Priority Review Zacks
06:30AM  Multinational Inflammatory Bowel Disease Survey Uncovers Striking Differences in Patients and Physicians Treatment Goals and Disease Management Expectations Business Wire
Feb-13-20 04:23PM  IBD 50 Stocks To Watch: BMY Stock Rebounds, As Celgene Benefits Kick In Investor's Business Daily
06:59AM  U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol-Myers Squibbs Biologics License Application (BLA) for Lisocabtagene Maraleucel (liso-cel) for Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma Business Wire
Feb-12-20 10:30AM  Buy AbbVie for its Growth Prospects, Yield and Low Valuation
Feb-11-20 05:24PM  Edited Transcript of BMY earnings conference call or presentation 6-Feb-20 1:30pm GMT Thomson Reuters StreetEvents
10:43AM  The Zacks Analyst Blog Highlights: Alibaba, Toyota Motor, Bristol-Myers Squibb, S&P Global and Uber Technologies Zacks
Feb-10-20 12:09PM  Q4 Earnings Season Scorecard and Analyst Reports for Alibaba, Toyota & Others Zacks
12:00PM  What Makes DHT Holdings (DHT) a New Strong Buy Stock Zacks
12:00PM  Radian (RDN) Upgraded to Buy: Here's Why Zacks
12:00PM  Fiat Chrysler (FCAU) Upgraded to Strong Buy: Here's Why Zacks
12:00PM  AC Immune (ACIU) Moves to Buy: Rationale Behind the Upgrade Zacks
05:54AM  This once-faltering cancer startup just raised $117M. Heres how it plans to spend it. American City Business Journals
05:41AM  Bristol-Myers Squibb Company Annual Results Just Came Out: Here's What Analysts Are Forecasting For Next Year Simply Wall St.
Feb-07-20 11:45AM  This is Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock Zacks
10:53AM  Bristol-Myers Squibb Rides Earnings To Composite Rating Hike Investor's Business Daily
10:24AM  Pharma Stock Roundup: BMY, GSK, SNY Q4 Results, MRK Earnings & Split Zacks
10:17AM  Company News for Feb 7, 2020 Zacks
09:45AM  How Trading Your Own Retirement Can Fleece Your Financial Future - February 07, 2020 Zacks
Feb-06-20 05:50PM  Can Biotech ETFs Continue to Soar in 2020? Zacks
05:20PM  Bristol-Myers Crushes Forecasts In Its First Post-Celgene Quarter Investor's Business Daily
04:56PM  Stock market clinches fresh closing records as China says it will slash tariffs on $75 billion in U.S. goods MarketWatch
04:28PM  Bristol-Myers Squibb Smashes Earnings Predictions Following Celgene Acquisition
03:45PM  Bristol-Myers' (BMY) Q4 Earnings & Revenues Beat Estimates Zacks
03:44PM  Stock Market in the Green on Thursday
03:36PM  CEO Q&A: Here's What You Need To Know About The New Bristol-Myers Investor's Business Daily
09:36AM  Bristol-Myers Tops Q4 Earnings Forecast as Celgene Takeover Boosts Bottom Line
08:35AM  Bristol-Myers Squibb (BMY) Surpasses Q4 Earnings and Revenue Estimates Zacks
08:29AM  Bristol-Myers Just Reported Earnings. Why Its Stock Is Jumping.
07:49AM  Bristol-Myers Squibb reports 33% jump in Q4 revenue, Opdivo sales fall 2% MarketWatch
07:47AM  The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs Benzinga
07:40AM  Stocks - US Futures Point Higher as China Cuts Tariffs
07:05AM  Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results for 2019 Business Wire
06:59AM  Bristol-Myers earnings rise due to Celgene deal Reuters
06:30AM  Bristol-Myers Squibb Co. to Host Earnings Call ACCESSWIRE
02:09AM  Bristol-Myers Squibb Earnings, Revenue Beat in Q4
Feb-05-20 04:11PM  13 Key NASH Drug Candidates To Watch For In A Potential $30-Billion Market Benzinga
06:34AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Feb-04-20 10:13AM  Will Opdivo & Eliquis Drive Bristol-Myers (BMY) Q4 Earnings? Zacks
Feb-03-20 07:04PM  3 Dividend-Paying Stocks for Investors to Buy to Fight Off Market Uncertainty Zacks
05:42PM  Bristol-Myers' Opdivo-Yervoy NSCLC Application in EU Withdrawn Zacks
10:18AM  Factors Setting the Tone for Bristol-Myers (BMY) Q4 Earnings Zacks
09:06AM  Powerful Proof Anyone Can Invest for an Early Retirement - February 03, 2020 Zacks
06:31AM  Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar? Zacks
Feb-01-20 10:56AM  Bernie Sanders surge in the polls could hit the S&P 500 with Iowa Caucus vote due this week, analysts warn MarketWatch
Jan-31-20 06:29PM  This Earnings Season Is Better Than You Think
04:16PM  CORRECTED-Bristol-Myers pulls Opdivo+Yervoy lung application in Europe Reuters
04:16PM  Bristol-Myers Squibb Withdraws European Application of Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Business Wire
08:54AM  Amgen (AMGN) Stock Down Despite Q4 Earnings & Revenue Beat Zacks
08:52AM  Amgen Beat Earnings Expectations. Heres Why Its Stock Is Dropping.
Jan-30-20 12:31PM  Analysts Estimate Bristol-Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for Zacks
09:08AM  Signs That Your Trading Will Ruin Your Retirement - January 30, 2020 Zacks
Jan-29-20 11:59AM  Oracle and 2 Other Stocks With Rising Prices That Still Look Cheap
Jan-28-20 05:45PM  Bristol-Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know Zacks
04:22PM  Acceleron (XLRN) Up on Success of PAH Drug in Phase II Study Zacks
10:20AM  Dr. Reddy's (RDY) Q3 Earnings and Revenues Increase Y/Y Zacks
10:20AM  Acceleron Stock Is Skyrocketing After Surprise Success for Heart Drug
06:37AM  Bristol-Myers Is a Buy During the Coronavirus Outbreak
Jan-27-20 09:26AM  Amgen (AMGN) to Report Q4 Earnings: What's in the Cards? Zacks
09:08AM  3 Biotech Stocks Nearing Support Investopedia
08:07AM  Roche Submits Application for Tecentriq-Avastin Combo in HCC Zacks
Jan-25-20 07:02AM  Are You An Income Investor? Don't Miss Out On Bristol-Myers Squibb Company (NYSE:BMY) Simply Wall St.
Jan-24-20 12:45PM  Here is Why Growth Investors Should Buy Bristol-Myers (BMY) Now Zacks
11:05AM  What Lies Ahead for Healthcare ETFs in Q4 Earnings? Zacks
10:52AM  Roche's Urothelial Cancer Study on Tecentriq Disappoints Zacks
10:27AM featured highlights include: SNX, ICHR, TECD, NSIT and BMY Zacks
09:31AM  Will Pfizer's (PFE) BioPharma Unit Boost Its Q4 Earnings? Zacks
09:12AM  J&J's Stelara Gets EU Nod for Plaque Psoriasis in Children Zacks
09:06AM  Want To Retire Early? Learn the Intelligent Investing Secret - January 24, 2020 Zacks
Jan-23-20 06:00PM  Gilead, Bristol-Myers Pumped More Into R&D Than Shareholder Enrichments
12:45PM  Index Fund Giants Draw Antitrust Scrutiny in U.S. Mergers Bloomberg
10:39AM  Amgen Stock Is Poised to Gain in 2020, Analyst Says. Heres Why.
Jan-22-20 05:45PM  Bristol-Myers Squibb (BMY) Flat As Market Gains: What You Should Know Zacks
10:03AM  Horizon Therapeutics Gets FDA Approval for Eye Drug Tepezza Zacks
09:28AM  The Extreme Risks of Trading Your Own Retirement Assets - January 22, 2020 Zacks
09:16AM  Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now? Zacks
07:04AM  5 Stocks Near a 52-Week High That Can Scale Higher Zacks
Jan-21-20 09:22AM  Top Ranked Momentum Stocks to Buy for January 21st Zacks
Jan-20-20 11:50AM  Should Value Investors Buy Bristol-Myers Squibb (BMY) Stock? Zacks
11:40AM  BMY or AZN: Which Is the Better Value Stock Right Now? Zacks
Jan-17-20 02:47PM  9 Takeaways From The JPMorgan Healthcare Conference Benzinga
09:35AM  Is Bristol-Myers Squibb (BMY) a Good Stock to Pick Now? Zacks
08:11AM  Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates Zacks
05:00AM  Top Picks 2020- Bristol-Myers Squibb BMY MoneyShow
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, the company offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus (HIV) and Evotaz; Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. Bristol-Myers Squibb Company has collaboration agreements with Nektar Therapeutics; Janssen Pharmaceuticals, Inc.; Biocartis Group NV.; FameWave Ltd.; Novartis; Presage Biosciences; and WindMIL Therapeutics, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
AHMED NADIMPresident, HematologyFeb 04Option Exercise0.002,076016,895Feb 06 08:48 PM
VESSEY RUPERTPres., Research & Early Dev.Feb 04Option Exercise0.003,592025,920Feb 06 08:49 PM
Elkins David VEVP, Chief Financial OfficerDec 31Option Exercise0.0012,373026,281Jan 03 07:00 PM
VESSEY RUPERTPres., Research & Early Dev.Dec 31Option Exercise0.0016,060030,778Jan 03 07:00 PM
Dubow AdamChief Compliance & Ethics OffiDec 05Sale58.811,740102,32915,749Dec 09 04:44 PM
Eid JosephSVPHead Global Medical AffairsDec 01Option Exercise0.002,82504,995Dec 03 05:28 PM
Schmukler Louis SPres., Global Mfg. & SupplyNov 05Sale56.5625,0001,414,00031,963Nov 06 04:54 PM
Elicker John ESVP, Public Affairs & IRNov 05Sale56.6615,000849,90074,471Nov 06 04:54 PM
Biondi PaulSVP, Head of Strategy & BDOct 02Option Exercise0.0059206,417Oct 03 04:46 PM
Santiago Karen MurphyControllerSep 01Option Exercise0.0064103,707Sep 04 05:17 PM
BERTOLINI ROBERT JDirectorJul 31Buy44.7211,000491,92011,397Aug 01 05:06 PM
Samuels Theodore R. IIDirectorMay 16Buy47.295,000236,44027,000May 20 04:36 PM
Santiago Karen MurphyControllerMay 16Sale47.563,065145,7713,066May 20 04:37 PM
Caforio GiovanniChairman and CEOMay 05Option Exercise0.008,0400373,239May 06 04:40 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerApr 03Option Exercise0.0011,594025,816Apr 05 04:32 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0014,180092,626Mar 13 07:42 AM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerMar 10Option Exercise0.0015,707014,501Mar 13 07:41 AM
Dubow AdamChief Compliance & Ethics OffiMar 10Option Exercise0.003,735018,240Mar 13 07:41 AM
Caforio GiovanniChairman and CEOMar 10Option Exercise0.00173,4190422,683Mar 13 07:40 AM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0062,2550411,547Mar 13 07:39 AM
Biondi PaulSVP, Head of Strategy & BDMar 10Option Exercise0.008,61907,860Mar 13 07:39 AM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0019,9250141,077Mar 13 07:38 AM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0026,568063,652Mar 13 07:37 AM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerMar 10Option Exercise0.005,864021,343Mar 13 07:36 AM
Santiago Karen MurphyControllerMar 10Option Exercise0.003,82506,850Mar 13 07:37 AM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0045,1700558,854Mar 13 07:35 AM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0025,577081,508Mar 13 07:34 AM
Bancroft Charles AEVP & Chief Financial OfficerFeb 28Option Exercise17.5152,884925,999392,690Mar 04 04:42 PM
LEUNG SANDRAEVP, General CounselFeb 28Option Exercise17.51169,8932,974,826634,478Mar 04 04:42 PM